Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. (Q35023711)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25125025%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

8 February 2021

Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25125025%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

protein kinase inhibitors

1 reference

2 October 2019

1 reference

14 September 2020

1 reference

8 February 2021

drug interaction

object of statement has role

subject heading

object named as

drug−drug interactions

1 reference

PubMed publication ID

pharmacokinetics

1 reference

based on heuristic

inferred from title

drug metabolism

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25125025%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

author name string

Yi Ling Teo

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25125025%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Han Kiat Ho

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25125025%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

language of work or name

0 references

publication date

1 February 2015

5 references

3 April 2019

2 October 2019

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25125025%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

14 September 2020

8 February 2021

British Journal of Clinical Pharmacology

5 references

3 April 2019

2 October 2019

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25125025%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

14 September 2020

8 February 2021

79

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25125025%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25125025%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

241-253

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25125025%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

copyright license

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

4 references

Europe PubMed Central

3 April 2019

Europe PubMed Central

2 October 2019

Europe PubMed Central

14 September 2020

Europe PubMed Central

8 February 2021

on focus list of Wikimedia project

0 references

Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Evidence for therapeutic drug monitoring of targeted anticancer therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Polypharmacy in elderly patients with cancer: clinical implications and management.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Optimizing Chemotherapy: Concomitant Medication Lists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Drug interactions in metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Metabolism considerations for kinase inhibitors in cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Anticancer oral therapy: emerging related issues.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: a Delphi survey of oncology pharmacists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

The Simcyp population-based ADME simulator

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Cytochrome P450s in the development of target-based anticancer drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Idiosyncratic drug reactions: current understanding

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Drug interactions in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Cytochrome P450 and anticancer drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Drug-drug interactions in oncology: why are they important and can they be minimized?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Drug interactions: Proteins, pumps, and P-450s

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4309630

8 July 2018

Potential drug-drug interactions at a referral hematology-oncology ward in Iran: a cross-sectional study.

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12496

21 January 2018

Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions.

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12496

21 January 2018

Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12496

21 January 2018

Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12496

21 January 2018

Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12496

21 January 2018

Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12496

21 January 2018

Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction.

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12496

21 January 2018

Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12496

21 January 2018

Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12496

21 January 2018

Are drug labels static or dynamic?

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12496

21 January 2018

Preventing adverse drug-drug interactions: a need for improved data and logistics

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12496

21 January 2018

Potential drug interactions and duplicate prescriptions among cancer patients

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12496

21 January 2018

Potential drug interactions in cancer patients receiving supportive care exclusively.

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12496

21 January 2018

Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12496

21 January 2018

Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite.

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12496

21 January 2018

Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12496

21 January 2018

Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants.

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12496

21 January 2018

Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12496

21 January 2018

Effect of gefitinib on warfarin antithrombotic activity

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12496

21 January 2018

Peripheral neuropathy on imatinib treatment for chronic myeloid leukaemia: suspected adverse drug interaction with amlodipine

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12496

21 January 2018

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12496

21 January 2018

Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12496

21 January 2018

Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25125025

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury

1 reference

https://pubmed.ncbi.nlm.nih.gov/25125025

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sunitinib in combination with clarithromycin or azithromycin - is there a risk of interaction or not?

1 reference

https://pubmed.ncbi.nlm.nih.gov/25125025

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine

1 reference

https://pubmed.ncbi.nlm.nih.gov/25125025

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?

1 reference

https://pubmed.ncbi.nlm.nih.gov/25125025

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human Metabolism of Lapatinib, a Dual Kinase Inhibitor: Implications for Hepatotoxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/25125025

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine

1 reference

https://pubmed.ncbi.nlm.nih.gov/25125025

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/BCP.12496

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25125025%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25125025%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25125025%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35023711&oldid=2164978434"